This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar cholangiocarcinoma with positively metastatic lymph nodes.
The patient must sign an informed consent form;
Age 18-75 years old, both male and female;
ECOG performance status score (PS score) 0 or 1 point;
Child-Pugh score A period;
Unresectable PHC patients or postoperative diagnosis of PHC recurrence and metastasis ;
Past or simultaneous suffering from other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ, and thyroid papillary carcinoma;
Have used gemcitabine-based chemotherapy or have used PD-1 monoclonal antibody or PD-L1 monoclonal antibody treatment within 6 months;
Severe cardiopulmonary and renal dysfunction;